The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2019 | Pacritinib moving forwards for myelofibrosis
Aaron Gerds, MD, MS, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, discusses the results of PAC2013 (NCT03165734), a randomized phase II dose-finding study of pacritinib in patients with myelofibrosis (MF) who were intolerant of or failed to benefit from ruxolitinib. Results from the study include pharmacokinetic and pharmacodynamic analyses, used to identify the recommended dose of pacritinib for further study. The optimal dose identified was generally well tolerated and demonstrated clinical activity, particularly in patients with severe thrombocytopenia, and phase 3 study (PACIFICA) is upcoming. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
